LINFAVENIX: improvement of signs and symptoms of chronic venous insufficiency and microangiopathy.
The aim of this independent study was to demonstrate the rapidity of the efficacy of an oral venotropic compound (Linfavenix, including natural elements) in patients with chronic venous insufficiency (CVI). Two groups of patients with chronic venous insufficiency (CVI) ankle swelling) were treated with Linfavenix or with below-knee elastic compression. The average ambulatory venous pressure (AVP) at inclusion (both groups)was 56.2 (range 48-55) with a refilling time (RT) shorter than 10 seconds. These parameters indicated a severe level of venous hypertension. There were no significant differences in AVP and RT between the two groups. The two groups of subjects with CVI were comparable; in the Linfavenix group there were 14 patients (age 44.5; sd 4; range 34-55; 7 females); in the elastic compression group there were 12 patients (45.4;5; range 36-56; 7 females). The clinical picture and microcirculatory parameters at inclusion were comparable. RF was comparable at inclusion in the two groups. At two weeks, the differences in RF (between goups) were not significant (the flux decreased in both groups, indicating improvement) while at 4 weeks the difference was larger (but non significant between the two groups) with a significant decrease in RF in the Linfavenix group. The RAS was also comparable at inclusion. Both groups had a significant decrease at 2 and 4 weeks. The decrease produced by Linfavenix after 4 weeks in RF was larger and significant (p<0.05) in comparison with the elastic compression group. Also the differences observed in ASLS were significant in both groups with an important, significant difference in favour of Linfavenix at 4 weeks (op<0.05) visibile as edema reduction. The decrease in edema was relevant in both groups at 2 (p<0.05) and 4 weeks (p<0.05) with a minimal but significant difference (p<0.05) between the Linfavenix and the elastic compression group. These variations in microcirculatory parameters indicate that the treatment with Linfavenix is, in its microcirculatory efficacy, at least comparable than elastic compression with is considered a standard therapeutic option in these patients. A significant level of improvement was reached with Linfavenix, in most patients (10/14) at 2 weeks for RF, at 7 days for the RAS and also at 2 weeks in almost all patients (13/14) considering ASLS and edema. No side effects due to treatment were observed. Compliance and tolerability were very good (no patient had to stop treatment; there were no drop-outs). In conclusion venous microangiopathy and edema were improved by the treatment with Linfavenix (better in comparison with compression) in a few days.
Cesarone
M R
MR
Irvine3 Vasc Lab and Physiology, Dept of Biomedical Sciences, Chieti-Pescara University, Chieti-Pescara, Italy.
Belcaro
G
G
Grossi
M G
MG
Pellegrini
L
L
Ledda
A
A
Vinciguerra
G
G
Ricci
A
A
Gizzi
G
G
Ippolito
E
E
Fano
F
F
Dugall
M
M
Cacchio
M
M
D000328:Adult; D031319:Aesculus; D000842:Ankle; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004338:Drug Combinations; D029962:Fagaceae; D005260:Female; D029501:Hamamelis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009754:Nuts; D008517:Phytotherapy / Q000379:methods*; D028321:Plant Preparations / Q000627:therapeutic use*; D031989:Pyrus; D031443:Ruscus; D031994:Sorbus; D053828:Stockings, Compression; D057049:Thrombotic Microangiopathies / Q000628:therapy*; D016896:Treatment Outcome; D029800:Vaccinium myrtillus; D014689:Venous Insufficiency / Q000503:physiopathology / Q000628:therapy*
D002317:Cardiovascular Agents; D004338:Drug Combinations; C546518:Linfavenix; D028321:Plant Preparations